News Home

Where Will Aprea Therapeutics Inc (APRE) Stock Go Next After It Is Up 7.85% in a Week?

Wednesday, December 08, 2021 10:56 AM | InvestorsObserver Analysts
Where Will Aprea Therapeutics Inc (APRE) Stock Go Next After It Is Up 7.85% in a Week?

Overall market sentiment has been high on Aprea Therapeutics Inc (APRE) stock lately. APRE receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Aprea Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on APRE!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With APRE Stock Today?

Aprea Therapeutics Inc (APRE) stock is up 7.85% while the S&P 500 is down -0.08% as of 10:56 AM on Wednesday, Dec 8. APRE has risen $0.30 from the previous closing price of $3.82 on volume of 179,630 shares. Over the past year the S&P 500 is higher by 26.84% while APRE is down -86.57%. APRE lost -$2.11 per share in the over the last 12 months. To screen for more stocks like Aprea Therapeutics Inc click here.

More About Aprea Therapeutics Inc

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). Click Here to get the full Stock Report for Aprea Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App